Thank you for choosing ACROBiosystems. Would you rate our product and service？
Spare 1 minute for the survey of bispecific antibody, get the gift of your choice from us!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Spare 1 minute for the survey of bispecific antibody, get the gift of your choice from us!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| VE2-H5255 | Human | Human VEGF R2 / KDR Protein, Fc Tag |  |
||
| VE2-HF254 | Human | FITC-Labeled Human VEGF R2 / KDR Protein, His Tag |  |
|
|
| VE2-M5258 | Mouse | Mouse VEGF R2 / KDR Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| KDR-H82E5 | Human | Biotinylated Human VEGF R2 / KDR Protein, Avitag™,His Tag |  |
|
|
| VE2-C52H3 | Rhesus macaque | Rhesus macaque VEGF R2 / KDR Protein, His Tag |  |
|
|
| KDR-H5280 | Human | Human VEGF R2 / KDR Protein, Strep Tag (MALS verified) |  |
|
|
| KDR-H5227 | Human | Human VEGF R2 / KDR Protein, His Tag (MALS verified) |  |
|
|
Loaded Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) on SA Biosensor, can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 482 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | EU | Leukemia, Myeloid, Acute; Mastocytosis | Novartis Europharm Ltd | 2017-04-28 | Hematologic Neoplasms; Leukemia; Mastocytosis, Systemic; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis | Details |
| Tivozanib | AV-951; KRN-951; ASP-4130; Kil-8951 | Approved | Kyowa Hakko Kirin Co Ltd | Fotivda | United States | Carcinoma, Renal Cell | Aveo Pharmaceuticals Inc | 2017-08-24 | Solid tumours; Carcinoma, Renal Cell; Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung | Details |
| Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | 多吉美, Nexavar | EU | Thyroid Neoplasms | Bayer Ag | 2005-12-01 | Liver Diseases; Neoplasm Metastasis; Fasting; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Thyroid Neoplasms; Hepatitis C; Hepatitis B; Breast Neoplasms; Liver Neoplasms; Neoplasms; Pancreatic Neoplasms; Kidney Diseases; Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Solid tumours; Ovarian Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Details |
| Pazopanib Hydrochloride | GW-786034; SB-786034; GSK-786034; GW-786034B | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Patorma, Votrient | Mainland China | Carcinoma, Renal Cell | Novartis Pharma Schweiz Ag | 2009-10-19 | Osteosarcoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Glioma; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Sarcoma; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Hemangiosarcoma; Carcinoma, Renal Cell; Solid tumours; Chondrosarcoma; Telangiectasia, Hereditary Hemorrhagic | Details |
| Fruquintinib | HMPL-013 | Approved | Hutchison Medipharma Ltd | 爱优特, Elunate | Mainland China | Colorectal Neoplasms | Hutchison Huangpu Medicine (Shanghai) Co Ltd | 2018-09-04 | Solid tumours; Rectal Neoplasms; Esophageal Neoplasms; Colonic Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Regorafenib Monohydrate | BAY-73-4506; DAST | Approved | Bayer Ag | Stivarga, Resihance | Mainland China | Gastrointestinal Stromal Tumors | Bayer Pharma Ag | 2012-09-27 | Solid tumours; Rectal Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms | Details |
| Axitinib | AG-013736; PF-01367866; AG-13736 | Approved | Pfizer Pharmaceuticals Ltd (China) | 英立达, Inlyta | Mainland China | Carcinoma, Renal Cell | Pfizer Europe Ma Eeig | 2012-01-27 | Kidney Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma; Skin Neoplasms; Myelodysplastic Syndromes; Endometriosis; Hepatic Insufficiency; Thyroid Neoplasms; Lung Neoplasms; Leukemia, Myeloid, Acute; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Macular Degeneration | Details |
| Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Small Cell Lung Carcinoma | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Thyroid Neoplasms; Sarcoma, Alveolar Soft Part; Cholangiocarcinoma; Lung Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Adenocarcinoma; Osteoma; Triple Negative Breast Neoplasms; Solid tumours; Ovarian Neoplasms; Leiomyosarcoma; Liver Neoplasms; Genital Diseases, Female; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Biliary Tract Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Sarcoma, Synovial; Neuroendocrine Tumors; Medullary thyroid cancer (MTC); Sarcoma | Details |
| Apatinib Mesylate | YN-968D1 | Approved | Advenchen Laboratories | 艾坦, Aitan | Mainland China | Stomach Neoplasms | Jiangsu shengdi Medicine Co Ltd | 2014-10-17 | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | Mainland China | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim International Gmbh | 2014-10-15 | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Scleroderma, Systemic; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Lung Diseases, Interstitial; Multiple Myeloma; Prostatic Neoplasms; Peritoneal Neoplasms; Hepatic Insufficiency; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Surufatinib | HMPL-012 | Approved | Hutchison Medipharma Ltd | 苏泰达, SULANDA | Mainland China | Neuroendocrine Tumors | Hutchison Huangpu Medicine (Shanghai) Co Ltd | 2020-12-29 | Biliary Tract Neoplasms; Pancreatic neuroendocrine tumors (pNET); Neoplasms; Kidney Diseases; Neuroendocrine Tumors; Bile Duct Neoplasms; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine | Details |
| Ramucirumab | IMC-1121; IMC-1C11; BLA-125477; IMC-1121-B; LY-3009806 | Approved | Dyax Pharma | Cyramza | United States | Carcinoma, Hepatocellular | Eli Lilly And Co Ltd | 2014-04-21 | Breast Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Ureteral Neoplasms; Peritoneal Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Urethral Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Solid tumours; Urinary Bladder Neoplasms; Microsatellite instability-high cancer; Colonic Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Rectal Neoplasms; Carcinoid Tumor; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Skin Melanoma; Biliary Tract Neoplasms | Details |
| Lenvatinib Mesylate | ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Endometrial Neoplasms | Eisai Inc | 2015-02-13 | Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gallbladder Neoplasms; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Sarcoma; Liver Diseases; Liver Neoplasms; Triple Negative Breast Neoplasms; Kidney Diseases; Small Cell Lung Carcinoma; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Esophageal Neoplasms; Renal Insufficiency; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Solid tumours | Details |
| Cabozantinib S-malate | BMS-907351; XL-184 | Approved | Exelixis Inc | Cometriq, Cabometyx | Japan | Carcinoma, Renal Cell | Takeda | 2012-11-29 | Solid tumours; Pain; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Glioblastoma; Kidney Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine; Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Sunitinib Malate | PHA-290940; SU-010398; SU-11248; GB-102; PNU-290940; SU-011248-L-malate salt; PNU-290940AD; PHA-290940AD | Approved | Pfizer Pharmaceuticals Ltd (China) | Sutent, 索坦 | Japan | Pancreatic neuroendocrine tumors (pNET) | Pfizer Inc | 2006-01-26 | Diabetic macular oedema; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Retinal Vein Occlusion; Carcinoma, Hepatocellular; Urogenital Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Prostatic Neoplasms; Breast Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Urologic Diseases; Kidney Diseases; Pancreatic neuroendocrine tumors (pNET); Pancreatic Neoplasms; Carcinoma, Islet Cell; Stomach Neoplasms; Carcinoma, Renal Cell; Solid tumours; Liver Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Shijiazhuang No.4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd | Liver Neoplasms; Stomach Neoplasms; Lung Neoplasms | Details |
| VEGFR-1/2 peptide vaccine (Keio University) | Phase 2 Clinical | Keio University | Neurofibromatoses; Brain Neoplasms; Glioma | Details | |
| VEGFR2 peptide vaccine (Tokyo University) | Phase 1 Clinical | University Of Tokyo | Pancreatic Neoplasms | Details | |
| Glesatinib | MG-90265; MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly | Phase 2 Clinical | Mirati Therapeutics | Carcinoma, Non-Small-Cell Lung | Details |
| VEGFR2 peptide vaccine (VAXIMM) | VXM-01 | Phase 2 Clinical | Merck Serono | Pancreatic Neoplasms; Glioblastoma; Colorectal Neoplasms; Glioma | Details |
| AVI-3207 | AVI-3207 | Phase 1 Clinical | Avixgen | Macular Degeneration | Details |
| Hydroxychloroquine/Sorafenib | Phase 1 Clinical | Vg Life Sciences | Ovarian Neoplasms | Details | |
| Orantinib | TSU-68; SU-6668; SU-006668 | Phase 2 Clinical | Pfizer Pharmaceuticals Ltd (China) | Liver Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular | Details |
| LMV-12(HE003) | LMV-12(HE003) | Phase 1 Clinical | Nanchang Hongyi Technology Co Ltd | Solid tumours | Details |
| Ramucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical) | Phase 1 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Telatinib | EOC-315; BAY-57-9352 | Phase 2 Clinical | Bayer Ag | Solid tumours; Stomach Neoplasms | Details |
| Ramucirumab biosimilar (CTTQ) | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Recombinant human anti-VEGFR2 monoclonal antibody (Buchang Pharma) | BC-001 | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Solid tumours | Details |
| Tafetinib Malate | SIM-0702; SIM-1005; SIM-010603 | Phase 1 Clinical | Jiangsu Xiansheng Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| MSB-0254 | MSB-0254 | Phase 1 Clinical | Mabspace Biosciences | Solid tumours | Details |
| Metatinib Trometamol | BMS-817378; SIM-817378 | Phase 1 Clinical | Bristol-Myers Squibb Company | Liver Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| HLX-12 | HLX-12 | Phase 1 Clinical | Shanghai Henlius Biotech Co Ltd | Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Kanitinib | CX-1003 | Phase 1 Clinical | Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Esa Biotech | Solid tumours; Esophageal Neoplasms; Prostatic Neoplasms | Details |
| SOMCL-15-290 | SOMCL-15-290 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Carcinoma, Squamous Cell | Details |
| Recombinant anti-VEGFR2 chimeric monoclonaly antibody (GeneScience) | Phase 2 Clinical | Changchun Genescience Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Sorafenib/MG-005 | MGD-1509 | Phase 1 Clinical | Metagone Biotech, Tri-Service General Hospital | Solid tumours | Details |
| BR-55 | BR-55 | Phase 2 Clinical | Sonus Pharmaceuticals | Ovarian Neoplasms; Prostatic Neoplasms | Details |
| Dovitinib | TKI-258; CHIR-258; GFKI-258; CHIR-258LC; NVP-TKI258 | Phase 2 Clinical | Novartis Pharma Ag | Carcinoma, Adenoid Cystic; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Leukemia, Myeloid, Acute; Thyroid Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Prostatic Neoplasms; Breast Neoplasms; Solid tumours; Adrenocortical Carcinoma; Multiple Myeloma; Pancreatic Neoplasms; Glioblastoma; Adenocarcinoma, Scirrhous; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Liver Neoplasms; Linitis Plastica; Stomach Diseases | Details |
| PAN-90806 | CP-632; OSI-632; CP-547632; PAN-90806 | Phase 2 Clinical | Pfizer Inc, Osi Pharmaceutical | Ovarian Neoplasms; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Diabetic Retinopathy; Macular Degeneration | Details |
| Cediranib | AZD2171; AZD-2171; NSC-732208 | Phase 2 Clinical | Astrazeneca Plc | Glioblastoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Hepatic Insufficiency; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Biliary Tract Neoplasms; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Liver Neoplasms; Leukemia; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
| Brivanib Alaninate | ZL-2301; BMS-540215; BMS-582664 | Phase 3 Clinical | Bristol-Myers Squibb Company | Solid tumours; Liver Neoplasms; Rectal Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Sarcoma; Colorectal Neoplasms; Gastrointestinal Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| AK-109 | AK-109 | Phase 2 Clinical | Kang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma | Details |
| CEP-11981 | ESK-981; CEP-11981; SSR-106462; BOL-303213X | Phase 2 Clinical | Sanofi | Prostatic Neoplasms | Details |
| Altiratinib | DP-5164; DCC-2701; DCC-22701; T-678746713 | Phase 1 Clinical | Deciphera | Solid tumours; Neoplasms | Details |
| Lucitanib | AL-3810; CO-3810; S-80881 | Phase 3 Clinical | Advenchen Laboratories Nanjing Ltd | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Thymus Neoplasms; Genital Neoplasms, Female; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| AXT-107 | AXT-107 | Phase 2 Clinical | AsclepiX Therapeutics Inc | Diabetic macular oedema; Macular Degeneration | Details |
| QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Stomach Neoplasms | Details |
| TAS-115 | TAS-115 | Phase 1 Clinical | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | Neoplasms | Details |
| JY-025 | JY-025 | Phase 3 Clinical | Beijing Jingyi Taixiang Technical Development Co Ltd, Beijing Eastern Biotech Co Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Olinvacimab | SSS-23; TTAC-0001 | Phase 2 Clinical | Pharmabcine | Glioblastoma; Triple Negative Breast Neoplasms; Neoplasm Metastasis | Details |
| Ningetinib Tosylate | CT-053; CT-053-PTSA | Phase 2 Clinical | Hec Pharm Co Ltd | Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Sitravatinib | MG-516; MG-91516; MGCD-516; IND-155305 | Phase 3 Clinical | Mirati Therapeutics | Solid tumours; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Hepatic Insufficiency; Ureteral Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular | Details |
| Chiauranib | CS-2164 | Phase 3 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Ovarian Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular | Details |
This web search service is supported by Google Inc.
A-Z